Researcher.Life Logo

Annals of Oncology : Impact Factor & More

eISSN: 1569-8041pISSN: 0923-7534

Aims and Scope of Annals of Oncology

The Annals of Oncology is a peer-reviewed medical journal of oncology, published by Elsevier. It is the official journal of the European Society for Medical Oncology. The editor-in-chief is Fabrice André (Villejuif, France). Previous editors were Jean-Charles Soria, Jan Vermorken, David J. Kerr and Franco Cavalli. Less

Key Metrics

CiteScore
47.3
Eigenfactor
0.1 - 0.5
Impact Factor
>= 25
Scite Index
0.88 5-Year SI
SJR
Q1Oncology
SNIP
6.79
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Annals of Oncology

Annals of Oncology Journal Specifications

Overview
Publisher ELSEVIER
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1990
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Annals of Oncology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Annals of Oncology

Erratum to 'Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis': [Annals of Oncology. Volume 36, Issue 11, November 2025, Pages 1389-1399
  • 7 Jan 2026
  • Annals of oncology : official journal of the European Society for Medical Oncology
Editorial Board
  • 1 Jan 2026
  • Annals of Oncology
Table of Contents
  • 1 Jan 2026
  • Annals of Oncology
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM).
  • 30 Dec 2025
  • Annals of oncology : official journal of the European Society for Medical Oncology
A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding "Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer" by Chen et al.
  • 20 Dec 2025
  • Annals of oncology : official journal of the European Society for Medical Oncology
The Achilles heel of precision AKT-targeted therapies in advanced prostate cancer: therapeutic promise constrained by the test.
  • 18 Dec 2025
  • Annals of oncology : official journal of the European Society for Medical Oncology
Erratum to 'Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis': [Annals of Oncology. Volume 36, Issue 11, November 2025, Pages 1389-1399
  • 7 Jan 2026
  • Annals of oncology : official journal of the European Society for Medical Oncology
Editorial Board
  • 1 Jan 2026
  • Annals of Oncology
Table of Contents
  • 1 Jan 2026
  • Annals of Oncology
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM).
  • 30 Dec 2025
  • Annals of oncology : official journal of the European Society for Medical Oncology
A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding "Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer" by Chen et al.
  • 20 Dec 2025
  • Annals of oncology : official journal of the European Society for Medical Oncology
The Achilles heel of precision AKT-targeted therapies in advanced prostate cancer: therapeutic promise constrained by the test.
  • 18 Dec 2025
  • Annals of oncology : official journal of the European Society for Medical Oncology

FAQs on Annals of Oncology